Benefit-to-harm ratio of the Danish breast cancer screening programme

scientific article

Benefit-to-harm ratio of the Danish breast cancer screening programme is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IJC.30758
P932PMC publication ID5488203
P698PubMed publication ID28470685

P50authorElsebeth LyngeQ39066029
Sisse Helle NjorQ47497377
P2093author name stringSisse Helle Njor
Anna-Belle Beau
Ilse Vejborg
Søren Nymand Lophaven
P2860cites workAbsolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in EnglandQ24629668
Breast Cancer Screening in DenmarkQ28735935
Breast cancer mortality in organised mammography screening in Denmark: comparative studyQ33751149
Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort studyQ33768755
Modern mammography screening and breast cancer mortality: population studyQ33770344
Interpreting overdiagnosis estimates in population-based mammography screeningQ34195837
Long-term effects of mammography screening: updated overview of the Swedish randomised trialsQ34579899
Breast cancer mortality in participants of the Norwegian Breast Cancer Screening ProgramQ34890406
Overdiagnosis of breast cancer in the Norwegian Breast Cancer Screening Program estimated by the Norwegian Women and Cancer cohort studyQ35078776
Regional trends in breast cancer incidence and mortality in Denmark prior to mammographic screeningQ36079460
Overdiagnosis in screening mammography in Denmark: population based cohort studyQ36638777
Overdiagnosis among women attending a population-based mammography screening program.Q37001743
Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program.Q39949342
Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.Q50665087
The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years.Q50701745
Decline in breast cancer mortality: how much is attributable to screening?Q53161042
The benefits and harms of breast cancer screening: an independent reviewQ57131263
Over-diagnosis estimate from The Independent UK Panel on Breast Cancer Screening is based on unsuitable dataQ59072557
Summary of the Evidence of Breast Cancer Service Screening Outcomes in Europe and First Estimate of the Benefit and Harm Balance SheetQ59073013
Extra incidence caused by mammographic screeningQ61881702
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectbreast cancer screeningQ17011492
P304page(s)512-518
P577publication date2017-05-03
P1433published inInternational Journal of CancerQ332492
P1476titleBenefit-to-harm ratio of the Danish breast cancer screening programme
P478volume141

Reverse relations

cites work (P2860)
Q99626163Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark
Q100736997In situ breast cancer incidence patterns in Iceland and differences in ductal carcinoma in situ treatment compared to Sweden
Q88933206Online information about risks and benefits of screening mammography in 10 European countries: An observational Web sites analysis
Q47241923Outcome of breast cancer screening in Denmark

Search more.